New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine
Summary
The FDA has approved a new flu vaccine called mFlusiva, made with mRNA technology like the COVID-19 vaccines. It is for adults 50 and older and aims to provide better protection, especially for older people who are more at risk from the flu.Key Facts
- mFlusiva is a flu vaccine using mRNA technology from Moderna.
- It is approved for people aged 50 and older.
- The vaccine showed about 27% fewer flu cases compared to another flu vaccine in adults 50-64.
- For adults 65 and older, the FDA gave accelerated approval, pending more studies.
- The vaccine may cause side effects like pain at the injection site, fever, headache, and tiredness.
- mRNA vaccines are quicker to produce, which helps if the flu virus changes suddenly.
- This is the first flu vaccine approved with mRNA technology.
- There was an earlier dispute at the FDA before the vaccine's approval, but independent advisers recommended its use.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
